% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman May 14, 2013 10:20 AM Flag


    ACAD is flying to the moon and now TSRX is starting to work. Cramer gave them a little PR last week and it's a little ST overbought, but still cheap in valuation compared to the market potential, it's worth a look. All IMO.

    If we can just get IMGN and ARNA working, I can play more golf!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It's too bad I was waiting for TSRX to dip back to low 6s after the positive trial announcement and was not able to buy in before the upgrades. ARNA on the other hand is already overpriced at 8. I would sell that once ARNA announces the milestone payment that goes with the launch. I still have some left that I might sell if pps gets close to 8.50.

13.46-0.82(-5.74%)Aug 31 4:00 PMEDT